These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Feb 25, 2019Pfenex to Host Conference Call and Webcast Reporting Fourth Quarter Financial Results on Monday, March 11th
SAN DIEGO, February 25, 2019-- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to...
Feb 19, 2019FDA Sets PDUFA Date of October 7, 2019
SAN DIEGO, February 19, 2019 —Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the 505(b)(2) New Drug Application (NDA)...
Dec 10, 2018Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of OsteoporosisSubmitted as a 505(b)(2) NDA with an Expected Ten-Month Review
SAN DIEGO, December 10, 2018-- Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of...
Nov 7, 2018On track to submit the NDA for PF708 to the FDA in fourth quarter of 2018
SAN DIEGO, November 7, 2018 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...